GU Cancer ESMO 2024 Highlights: Key Studies Discussed NIAGARA, TiNiVO-2, PEACE-3, CONTACT-02

2024-10-03

Join us as we dive into four pivotal studies: 1.⁠ ⁠NIAGARA Trial: Explore the groundbreaking findings on the combination of chemotherapy and immunotherapy in the perioperative setting for patients with resectable muscle-invasive bladder cancer, which may now set a new standard of care. 2.⁠ ⁠TiNiVO-2 Study: Learn why re-challenging patients with immunotherapy after progression on prior immunotherapy is not recommended, and what alternative treatments may be more effective. 3.⁠ ⁠PEACE-3 Study: Discover th...

Join us as we dive into four pivotal studies:

1.⁠ ⁠NIAGARA Trial: Explore the groundbreaking findings on the combination of chemotherapy and immunotherapy in the perioperative setting for patients with resectable muscle-invasive bladder cancer, which may now set a new standard of care.

2.⁠ ⁠TiNiVO-2 Study: Learn why re-challenging patients with immunotherapy after progression on prior immunotherapy is not recommended, and what alternative treatments may be more effective.

3.⁠ ⁠PEACE-3 Study: Discover the implications of combining enzalutamide with radium-223 in metastatic castration-resistant prostate cancer and its impact on progression-free survival.

4.⁠ ⁠CONTACT-02 Study: Understand the results comparing cabozantinib with atezolizumab against a second novel hormonal therapy, and what this means for overall survival in specific patient populations.

Tune in for an insightful discussion that highlights the latest advancements in GU cancer treatment and their potential impact on clinical practice. Don't forget to check out our other episodes covering breast cancer, lung cancer, and GI malignancies from ESMO 2024!

Subscribe for more updates and insights from the Oncology Brothers!

Website: http://www.oncbrothers.com/

Twitter: https://twitter.com/oncbrothers

Comments (3)